https://doi.org/10.4081/aiua.2023.11313

HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones

Vol. 95 No. 2 (2023)
Submitted: March 14, 2023
Accepted: April 1, 2023
Published: May 30, 2023
Transurethral resection, Non-Muscle-Invasive Urothelial Carcinoma, C-erbB-2, Bacillus Calmette Guerin, Immunohistochemistry
Abstract Views: 909
PDF: 376
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Mohamed Yousef Ali
Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ahmed Yousef Aboelsaad
Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Ahmed M. Abdel Gawad
https://orcid.org/0000-0001-7051-6019
Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Tamer A. Abouelgreed
Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Ahmed A. El Gammal
https://orcid.org/0000-0002-6784-1790
Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Osama M. Ghoneimy
https://orcid.org/0000-0002-8207-3451
Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Eman M. El-Dydamony
Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Ahmed A Alrefaey
Urology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Eslam Mohamed
Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Sherif Azzam
Clinical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ayman Abdulmohaymen
Surgical Oncology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Yasien Mohammed
https://orcid.org/0000-0002-1290-5910
Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohammed S. Abdelwahed
Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo; Pathology Department, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia, Egypt.
Ahmed Fawzi A. Elsayed
Urology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Basem A. Fathi
https://orcid.org/0000-0001-8245-5428
Urology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Nosaiba M. Abd Alrahim
Clinical pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Abeer S. Farag
Pathology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Alaa R. Mahmoud
Urology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Hasan Ismail Mohamed
Urology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Seth Horsu
Histopathology Department, St. Vincent’s University Hospital, Dublin, Ireland.
Abdulkarim Hasan
doctorabdulkarim7@gmail.com
https://orcid.org/0000-0003-0391-306X
Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Background: Transurethral resection (TUR) followed by adjuvant therapy is still the treatment of choice of Non-Muscle-Invasive Bladder Urothelial Carcinoma (NMIBUC). However, recurrence is one of the most troublesome features of these lesions. Early second resection and adjuvant BCG therapy has been shown to improve the outcome. Objective: To evaluate the prognostic value of C-erbB-2 (HER2/neu) expression status in Non-Muscle-Invasive Bladder Urothelial Carcinoma cases, before and after intravesical Bacillus Calmette Guerin (BCG immunotherapy). Materials and methods: HER2/neu expression was studied in 120 (Ta-T1) Non-Muscle-Invasive Urothelial Carcinoma cases. The expression was evaluated and compared to the expression after Bacillus Calmette Guerin (BCG) immunotherapy. Results: HER2/neu expression in low and high grade of the Non- Muscle-Invasive Urothelial Carcinoma was (38%) and (83%) respectively. The difference of the expression rates by tumor grade was statistically significant. In recurring lesions post BCG therapy, C-erbB-2 expression was markedly decreased (31.6%) when compared to its expression before therapy (65%). Conclusions: The HER2/neu expression increased as the tumor grade rose. The reduction in expression following BCG treatment in Non-Invasive transitional cell carcinoma cases could reflect a reduction of the potential malignancy of the tumor.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Compérat E, Larré S, Roupret M, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015; 466:589.
Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non muscle-invasive urothelial carcinoma of the bladder (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019; 76:639-657.
de Goeij L, Westhoff E, Witjes JA, et al. The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle- invasive bladder cancer prognosis and health-related quality of life. BMJ Open. 2019; 9:e030396.
Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56:247-256.
Zhao J, Xu W, Zhang Z, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2015; 47:87-94.
Babjuk M, Burger M, Compérat E. EAU guidelines on non-muscle-invasive bladder cancer. Arnhem, The Netherlands: European Association of Urology; 2022. https://uroweb.org/guideline/non-muscle invasive-bladder-cancer/
Ramezani M, Siami, S, Rezaei M, et al. Immunohistochemical Study of c-erbB2/HER2 Tumor Marker in Primary Malignant Brain Tumors. Preprints.org 2018, 2018120017. https://doi.org/10.20944/ preprints 201812.0017.v1.
Ali MY, El-Esawy BH. Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy. Egyptian Journal of Pathology. 2014; 34:25-31.
Remy E, Rebouissou S, Chaouiya C, et al. A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis Mathematical Model of Bladder Tumorigenesis. Cancer Res. 2015; 75:4042-4052.
Hegazy R, Kamel M, Salem EA, et al. The prognostic significance of p53, p63 and Her2 expression in nonmuscle- invasive bladder cancer in relation to treatment with bacille Calmette-Guerin. Arab J Urol. 2015; 13:225-230.
Kumar S, Prajapati O, Vaiphei K, et al. Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: is it worth hype? South Asian J Cancer. 2015; 4:115-117.
Agrawal V, Bharti N, Pandey R. Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy. Arab Journal of Urology. 2020; 18:267-72.
Eriksson P, Rovira C, Liedberg F, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018; 8:1-2.
Bellmunt J, Werner L, Bamias A, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015; 4:844-852.
Akgül M, Baykan Ö, Çag˘man Z, et al. Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer. Arch Ital Urol Androl. 2021; 93:148-152.
Mitrakas L, Gravas S, Karasavvidou F, et al. Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer. Arch Ital Urol Androl. 2021; 93:143-147.
Lim SD, Cho YM, Choi GS, et al. Clinical significance of substaging and HER2 expression in papillary non-muscle invasive urothelial cancers of the urinary bladder. J Korean Med Sci. 2015; 30:1068-1077.
Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010; 57:766-773.
Morgan BE, Salup R, Morgan MB. Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder. Urol Oncol. 2002; 7:67-72.
Trigo S, Gonzalez K, Di Matteo L, et al. Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis. Arch Ital Urol Androl. 2021; 93:1-8.

How to Cite

Ali, M. Y., Aboelsaad, A. Y., Abdel Gawad, A. M., Abouelgreed, T. A., El Gammal, A. A., Ghoneimy, O. M., El-Dydamony, E. M., Alrefaey, A. A., Mohamed, E., Azzam, S., Abdulmohaymen, A., Mohammed, Y., Abdelwahed, M. S., Elsayed, A. F. A., Fathi, B. A., Abd Alrahim, N. M., Farag, A. S., Mahmoud, A. R., Mohamed, H. I., Horsu, S., & Hasan, A. (2023). HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones. Archivio Italiano Di Urologia E Andrologia, 95(2). https://doi.org/10.4081/aiua.2023.11313
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.